The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

Spasmium comp. 500 mg/ml + 4 mg/ml solution for injection

500.0/4.0 milligram(s)/millilitre Solution for injection

Richter Pharma AGVPA10801/008/001

Main Information

Trade NameSpasmium comp. 500 mg/ml + 4 mg/ml solution for injection
Active SubstancesMetamizole sodium monohydrate
Hyoscine butylbromide
Strength500.0/4.0 milligram(s)/millilitre
Dosage FormSolution for injection
Licence HolderRichter Pharma AG
Licence NumberVPA10801/008/001

Group Information

ATC CodeQA03DB04 butylscopolamine and analgesics
Therapeutic ClassN.S.A.I.D.


Licence Issued18/09/2015
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back